3D pharmacophore based virtual screening of A2A adenosine receptor antagonists

Protein and Peptide Letters

Volumn 17, Issue 3, 2010, Pages 332-339

  Wei, Jing ^a   Qu, Wanlu ^a   Ye, Yingda ^a   Gao, Qingzhi ^a  

^a TIANJIN UNIVERSITY   (China)

Author keywords

A2a; Adenosine receptor antagonists; Docking; Pharmacophore based virtual library screening

Indexed keywords

ADENOSINE A2A RECEPTOR; ENZYME INHIBITOR; TRIAZOLE DERIVATIVE;

ARTICLE; BINDING SITE; CHEMISTRY; DRUG ANTAGONISM; DRUG DELIVERY SYSTEM; DRUG DEVELOPMENT; HUMAN; METABOLISM; METHODOLOGY; MOLECULAR DYNAMICS; PROTEIN BINDING; REPRODUCIBILITY;

BINDING SITES; DRUG DELIVERY SYSTEMS; DRUG DISCOVERY; ENZYME INHIBITORS; HUMANS; MOLECULAR DYNAMICS SIMULATION; PROTEIN BINDING; RECEPTOR, ADENOSINE A2A; REPRODUCIBILITY OF RESULTS; TRIAZOLES;

EID: 77949955149     PISSN: 09298665     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986610790780260     Document Type: Article

References (55)

1. Fredholm, B. B.; IJzerman A. P.; Jacobson, K. A.; Klotz, K.-A.; Linden, J. International union of pharmacology. XXV. nomenclature and classification of adenosine receptors. Pharmacol. Rev., 2001, 53(4), 527-552.
2. Hourani S. M.; Boon, K.; Fooks, H. M.; Prentice, D. J. Role of cyclic nucleotides in vasodilatations of the rat thoracic aorta induced by adenosine analogues. Br. J. Pharmacol., 2001, 133(6), 833-840.
3. Pinna, A.; Wardas, J.; Simola, N.; Morelli, M. New therapies for the treatment of Parkinson's disease: Adenosine A2A receptor antagonists. Life Sci., 2005, 77(26), 3259-3267.
4. Sitkovsky, M. V. Physiological control of immune response and inflammatory tissue damage by hypoxia inducible factors and adenosine A2A receptors. Annu. Rev. Immunol., 2004, 22, 2101-2126.
5. Sitkovsky, M.; Lukashev, D. Regulation of immune cells by local-tissue oxygen tension: HIF1 and adenosine receptors. Nat. Rev. Immunol., 2005a, 5(9), 712-721.
6. Ohta, A.; Gorelik, E.; Prasad, S. J.; Ronchese, F.; Lukashev, D.; Wong, M. K. A2A adenosine receptor protects tumors from antitumor T cells. Proc. Natl. Acad. Sci. USA, 2006, 103(35), 13132-13137.
7. Grondin, R.; Bedard, P. J.; Hadj Tahar, A.; Gregoire, L.; Mori, A.; Kase, H. Antiparkinsonian effect of a new selective adenosine A2A receptor antagonist in MPTP-treated monkeys. Am. Acad. Neurol., 1999, 52(8), 1673-1677.
8. Sitkovsky, M.; Lukashev, D.; Deaglio, S.; Dwyer, K.; Robson, S. C.; Ohta, A. Adenosine A2A receptor antagonists: Blockade of adenosinergic effects and T regulatory cells. Br. J. Pharmacol., 2008, 153(S1), S457-S464.
9. Bockaert, J.; Pin, J. P. Molecular tinkering of G protein-coupled receptors: An evolutionary success. EMBO J., 1999, 18(7), 1723-1729.
10. Ivanov, A. A.; Baskin, I. I.; Palyulin; V. A.; Zefirov, N. S. Molecular modeling the human A1 adenosine receptor and study of the mechanisms of its selective ligand binding. Dokl. Biochem. Bio-phys., 2002, 386(4), 271-274.
11. Ivanov, A. A.; Baskin, I. I.; Palyulin, V. A.; Zefirov, N. S. Molecular modeling of the human A2A adenosine receptor. Dokl. Bio-chem. Biophys., 2003, 389(3), 94-97.
12. Ivanov, A. A.; Baskin, I. I.; Palyulin, V. A.; Piccagli, L.; Baraldi, P. G.; Zefirov, N. S. Molecular modeling and molecular dynamics simulation of the human A2B adenosine receptor. The study of the possible binding modes of the A2B receptor antagonists. J. Med. Chem., 2005, 48(22), 6813-6820.
13. Stefano, M.; Giampiero, S.; Kenneth, A. J. Techniques: Recent developments in computer-aided engineering of GPCR ligands using the human adenosine A3 receptor as an example. Trends Pharmacol. Sci., 2005, 26(1), 44-51.
14. Chou, K. C.; Shen, H. B. Cell-PLoc: A package of web-servers for predicting subcellular localization of proteins in various organisms. Nat. Protocols, 2008, 3(2), 153-162.
15. Chou, K. C.; Shen, H. B. Review: Recent progresses in protein subcellular location prediction. Anal. Biochem., 2007, 370(1), 1-16.
16. Chou, K. C.; Shen, H. B. Euk-mPLoc: a fusion classifier for large-scale eukaryotic protein subcellular location rediction by incorporating multiple sites. J. Proteome Res., 2007, 6(5), 1728-1734.
17. Shen, H. B.; Chou, K. C. QuatIdent: A web server for identifying protein quaternary structural attribute by fusing functional domain and sequential evolution information. J. Proteome Res., 2009, 8(3), 1577-1584.
18. Xiao, X.; Wang, P.; Chou, K. C. Predicting protein quaternary structural attribute by hybridizing functional domain composition and pseudo amino acid composition. J. Appl. Cryst., 2009, 42(2), 169-173.
19. Xiao, X.; Wang, P.; Chou, K. C. GPCR-CA: A cellular automaton image approach for predicting G-protein-coupled receptor functional classes. J. Comput. Chem., 2009, 30(9), 1414-1423.
20. Chou, K. C.; Shen, H. B. ProtIdent: A web server for identifying proteases and their types by fusing functional domain and sequential evolution information. Biochem. Biophys. Res. Commun., 2008, 376(2), 321-325.
21. Shen, H. B.; Chou, K. C. Identification of proteases and their types. Anal. Biochem., 2009, 385(1), 153-160.
22. Chou, K. C. A vectorized sequence-coupling model for predicting HIV protease cleavage sites in proteins. J. Biol. Chem., 1993, 268(23), 16938-16948.
23. Chou, K. C. Review: Prediction of HIV protease cleavage sites in proteins. Anal. Biochem., 1996, 233(1), 1-14.
24. Shen, H.B; Chou, K. C. HIVcleave: a web-server for predicting HIV protease cleavage sites in proteins. Anal. Biochem., 2008, 375(2), 388-390.
25. Chou, K. C.; Shen, H. B. Signal-CF: a subsite-coupled and window-fusing approach for predicting signal peptides. Biochem. Bio-phys. Res. Commun., 2007, 357(3), 633-640.
26. Shen, H. B.; Chou, K. C. Signal-3L: a 3-layer approach for predicting signal peptide. Biochem. Biophys. Res. Commun., 2007, 363(2), 297-303.
27. Du, Q.S.; Huang, R.B.; Chou, K. C. Review: Recent advances in QSAR and their applications in predicting the activities of chemical molecules, peptides and proteins for drug design. Curr. Protein Pept. Sci., 2008, 9(3), 248-259.
28. Du, Q.S.; Huang, R.B.; Wei, Y.T.; Pang, Z.W.; Du, L.Q.; Chou, K. C. Fragment-based quantitative structure-activity relationship (FB-QSAR) for fragment-based drug design. J. Comput. Chem., 2009, 30(2), 295-304.
29. Prado-Prado, F.J.; Gonzalez-Diaz, H.; de la Vega, O.M.; Ubeira, F.M.; Chou, K. C. Unified QSAR approach to antimicrobials. Part 3: First multi-tasking QSAR model for Input-Coded prediction, structural back-projection, and complex networks clustering of antiprotozoal compounds. Bioorg. Med. Chem., 2008, 16(11), 5871-5880.
30. Prado-Prado, F.J.; Martinez de la Vega, O.; Uriarte, E.; Ubeira, F.M.; Chou, K. C.; Gonzalez-Diaz, H. Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks. Bioorg. Med. Chem., 2009, 17(2), 569-575.
31. Chou, K. C. Review: Structural bioinformatics and its impact to biomedical science. Curr. Med. Chem., 2004, 11(16), 2105-2134.
32. Chou, K. C.; Wei, D. Q.; Du, Q. S.; Sirois, S. & Zhong, W. Z. Review: Progress in computational approach to drug development against SARS. Curr. Med. Chem., 2006, 13(27), 3263-3270.
33. Chou, K. C. Insights from Modelling the 3D structure of the extracellular domain of alpha-7 nicotinic acetylcholine receptor. Bio-chem. Biophys. Res. Commun., 2004, 319(2), 433-438.
34. Chou, K. C. Insights from modeling the tertiary structure of human BACE2. J. Proteome Res., 2004, 3(5), 1069-1072.
35. Du, Q. S.; Wang, S.; Wei, D. Q.; Sirois, S.; Chou, K. C. Molecular modelling and chemical modification for finding peptide inhibitor against SARS CoV Mpro. Anal. Biochem., 2005, 337(2), 262-270.
36. Huang, R. B.; Du, Q. S.; Wang, C. H.; Chou, K. C. An in-depth analysis of the biological functional studies based on the NMR M2 channel structure of influenza A virus. Biochem. Biophys. Res. Commun., 2008, 377(4), 1243-1247.
37. Schnell, J. R.; Chou, J. J. Structure and mechanism of the M2 proton channel of influenza A virus. Nature, 2008, 451(7178), 591-595.
38. Wei, D. Q.; Du, Q. S.; Chou, K. C. Virtual screening for SARS-CoV protease based on KZ7088 pharmacophore points. J. Chem.Inf. Comput. Sci., 2004, 44(3), 1111-1122.
39. Baraldi, P. G.; Cacciari, B.; Romagnoli, R.; Spalluto, G.; Monopoli, A.; Ongini, E.; Varani, K.; Borea, P. A. 7-Substituted 5-amino-2-(2-furyl)pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines as A2A adenosine receptor antagonists: A study on the importance of modifications at the side chain on the activity and solubility. J. Med. Chem., 2002, 45(1), 115-126.
40. Peng, H.; Kumaravel, G.; Yao, G.; Sha, L.; Wang, J.; Vlijmen, H. V.; Bohnert, T.; Huang, C.; Vu, C. B.; Ensinger, C. L.; Chang, H.; Engber, T. M.; Whalley, E. T.; Petter, R. C. Novel bicyclic piperazine derivatives of triazolotriazine and triazolopyrimidines as highly potent and selective adenosine A2A receptor antagonists. J. Med. Chem., 2004, 47(25), 6218-6229.
41. Chou, K. C.; Watenpaugh, K. D.; Heinrikson, R. L. A model of the complex between cyclin-dependent kinase 5 and the activation domain of neuronal Cdk5 activator. Biochem. Biophys. Res. Commun., 1999, 259(2), 420-428.
42. Du, Q. S.; Wang, S. Q.; Jiang, Z. Q.; Gao, W. N.; Li, Y. D.; Wei, D. Q.; Chou, K. C. Application of bioinformatics in search for cleavable peptides of SARS-CoV Mpro and chemical modification of octapeptides. Med. Chem., 2005b, 1(3), 209-213
43. Ye, Y.; Wei, J.; Dai, X.; Gao, Q. Computational studies of the binding modes of A2A adenosine receptor antagonists. Amino Ac- ids, 2008, 35(2), 389-396.
44. Gao, W. N.; Wei, D. Q.; Li, Y.; Gao, H.; Xu, W. R.; Li, A. X.; Chou, K. C. Agaritine and its derivatives are potential inhibitors against HIV proteases. Med. Chem., 2007, 3(3), 221-226.
45. Li, L.; Wei, D. Q.; Wang, J. F.; Chou, K. C. Computational studies of the binding mechanism of calmodulin with chrysin. Biochem. Biophys. Res. Commun., 2007, 358(4), 1102-1107.
46. Chou, K. C.; Jones, D.; Heinrikson, R.L. Prediction of the tertiary structure and substrate binding site of caspase-8. FEBS Lett., 1997, 419(1), 49-54.
47. Chou, K. C.; Tomasselli, A. G.; Heinrikson, R. L. Prediction of the tertiary structure of a caspase-9/inhibitor complex. FEBS Lett., 2000, 470(3), 249-256.
48. Chou, K. C.; Wei, D. Q.; Zhong, W. Z. Binding mechanism of coronavirus main proteinase with ligands and its implication to drug design against SARS. Biochem. Biophys. Res. Commun., 2003, 308(1), 148-151.
49. Chou, K. C. Molecular therapeutic target for type-2 diabetes. J. Proteome Res., 2004, 3(4), 1284-1288.
50. Kim, J.; Wess, J.; Van, R. A.M.; Schoneberg, T.; Jacobson, K. A. Site-directed mutagenesis identifies residues involved in ligand recognition in the human A2A adenosine receptor. J. Biol. Chem., 1995, 270(23), 13987-13997.
51. Barbara, C.; Giorgia, P.; Giampiero, S. Medicinal chemistry of A2A adenosine receptor antagonists. Curr. Top. Med. Chem., 2003, 3(4), 403-411.
52. Smellie, A.; Teig, S. L.; Towbin, P. Poling: Promoting conforma- tional variation. J. Comput. Chem., 1995, 16(2), 171-187.
53. Catalyst, version 4.10; Accelrys Inc.: San Diego, USA, 2005.
54. Catalyst 4.10 Tutorials: http://www.accelrys.com/doc/pdf/index.html
55. Du, Q. S.; Wei, Y. T.; Pang, Z. W.; Chou, K. C.; Huang, R. B. Predicting the affinity of epitope-peptides with class I MHC molecule HLA-A*0201: an application of amino acid-based peptide prediction. Protein Eng. Des. Sel., 2007, 20(9), 417-423.